Co-Diagnostics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $11,884,607 | $2,936,544 |
| Marketable investment securities | - | 26,811,098 |
| Accounts receivable, net | 190,375 | 132,570 |
| Inventory, net | 992,397 | 1,072,724 |
| Income taxes receivable | 44,559 | - |
| Prepaid expenses and other current assets | 581,527 | 1,338,762 |
| Total current assets | 13,693,465 | 32,291,698 |
| Property and equipment, net | 2,272,098 | 2,761,280 |
| Operating lease right-of-use asset | 1,207,453 | 2,114,876 |
| Intangible assets, net | 7,219,000 | 26,101,000 |
| Investment in joint ventures | 350,569 | 294,304 |
| Total assets | $24,742,585 | $63,563,158 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $1,878,225 | $3,294,254 |
| Accrued expenses | 865,301 | 2,562,169 |
| Operating lease liability, current | 662,258 | 915,619 |
| Contingent consideration liabilities, current | 119,036 | 502,819 |
| Deferred revenue | 14,800 | 40,857 |
| Total current liabilities | 3,539,620 | 7,315,718 |
| Long-term liabilities | ||
| Income taxes payable | - | 713,643 |
| Operating lease liability | 574,301 | 1,236,560 |
| Contingent consideration liabilities | - | 422,080 |
| Total long-term liabilities | 574,301 | 2,372,283 |
| Total liabilities | 4,113,921 | 9,688,001 |
| Commitments and contingencies (Note 13) | - | - |
| Stockholders’ equity | ||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 2025 and 1,263,408 shares issued and 1,101,785 shares outstanding as of December 31, 2024 | 67,700 | 37,902 |
| Treasury stock, at cost; 161,623 shares held as of December 31, 2025 and December 31, 2024, respectively | (15,575,795) | (15,575,795) |
| Additional paid-in capital | 116,510,298 | 102,472,210 |
| Accumulated other comprehensive income | - | 418,443 |
| Accumulated deficit | (80,373,539) | (33,477,603) |
| Total stockholders’ equity | 20,628,664 | 53,875,157 |
| Total liabilities and stockholders’ equity | $24,742,585 | $63,563,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.